Peer-reviewed veterinary case report
Liquid biopsy predicts chemo response in dogs with lymphoma
By Taismara K. Garnica et al.·Published in Scientific Reports·2020·Laboratory of Comparative and Translational Oncology (LOCT), Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of Sao Paulo, GB·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas
- Species:
- dog
Plain-English summary
A study looked at 19 dogs with multicentric lymphoma, a common type of cancer in dogs, to see if a new blood test could predict how well they would respond to chemotherapy. The dogs were treated with a standard chemotherapy protocol and were evaluated after 19 weeks. The results showed that dogs who did not respond to treatment had higher levels of certain small particles in their blood compared to those who did respond. This new liquid biopsy method could help veterinarians identify which dogs might need different treatments sooner, potentially improving outcomes for pets with this serious condition.
People also search for: dog lymphoma treatment · chemotherapy response in dogs · liquid biopsy for dog cancer
Abstract
Abstract Lymphoma is the most common type of canine hematological malignancy where the multicentric (cMCL) form accounts for 75% of all cases. The standard treatment is the CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone, where the majority of dogs achieve complete/partial response; however, it is very important to predict non-responsive cases to improve treatment and to develop new targeted therapies. Here we evaluate a liquid biopsy approach based on serum Small Extracellular Vesicles enriched for exosomes (SEVs) to predict cMCL chemotherapy response. Nineteen dogs at the end of the 19-week chemotherapy protocol (8 Complete Response and 11 Progressive Disease) were evaluated for serum SEVs size, concentration and screened for 95 oncomirs. PD patients had higher SEVs concentration at the diagnosis than CR patients (P = 0.034). The ROC curve was significant for SEVs concentration to predict the response to CHOP (AUC = 0.8011, P = 0.0287). A potential molecular signature based on oncomirs from SEVs (caf-miR-205, caf-miR-222, caf-mir-20a and caf-miR-93) is proposed. To the best of our knowledge, this is the first study demonstrating the potential of a liquid biopsy based on SEVs and their miRNAs content to predict the outcome of chemotherapy for canine multicentric lymphomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.1038/s41598-020-77366-7